Shares of Zomedica Pharmaceuticals ( NYSEMKT:ZOM) fell 13.7% on Thursday after the veterinary health company announced a change to its sales strategy. Zomedica will build out its internal sales team as it transitions away from its current distributor-based approach.
Full Answer
Is zomedica stock a buy at 35 cents a share?
Mar 23, 2021 · Zomedica's recent stock price movements appear to be a classic "buy the rumor, sell the news" event. Traders on Reddit and other social media sites have hyped Zomedica's growth prospects in recent ...
Did zomedica surrender some of its recent gains?
Apr 15, 2021 · CEO Robert Cohen said the move was precipitated by "changes at our current distributor that we believe have impacted its ability to market our products effectively." Those words likely startled...
Why did Zom stock drop after launching truforma?
Feb 09, 2021 · Later on Monday night, Zomedica said it was increasing the size of its stock offering to more than 91.3 million shares "due to demand." Zomedica said gross proceeds from the stock sale would now ...
What happened to Zom stock in 2021?
Apr 06, 2021 · Why Zomedica stock is dropping Over the last month, investors have exited speculative stocks like ZOM. Also, given the rising bond yields, there has been a sell-off in companies whose cash flows...
Why is Zomedica stock falling?
The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.Nov 18, 2021
Is Zomedica a good stock to buy?
In the final analysis, ZOM stock is highly risky and best suited for speculative traders. Yet it's possible that retail traders will bid the stock up in 2022. And if they abandon Zomedica, it would be a dog-gone shame.Jan 7, 2022
Is Zomedica expected to rise?
Zomedica Corp (NYSE American:ZOM) The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +292.16% increase from the last price of 0.31.
Why did Zomedica stock go up?
The big jump came after the veterinary health company provided a sneak peek at its 2021 fourth-quarter and full-year revenue following the market close on Friday. Zomedica reported total revenue in the fourth quarter and full-year 2021 of $4.1 million.Feb 28, 2022
Could Zomedica be a millionaire maker?
The biggest reason Zomedica might not be a millionaire-maker stock is that the business has a long way to go in showing that it can generate strong sales numbers. And that's ultimately going to be tied to whether Truforma is successful or not.May 19, 2021
Will Zomedica get delisted?
The NYSE American LLC told Zomedica that it's no longer in danger of being delisted. The exchange can remove a stock if it closes at less than $1 for more than 30 consecutive days. That's no longer the case for Zomedica.Feb 19, 2021
Will Zomedica go up tomorrow?
Tomorrow's movement Prediction of Zomedica Pharmaceuticals Corp ZOM as on 08 Apr 2022 appears strongly Bullish. This stock started moving upwards as soon as it opened....Munafa value: 55 as on 08 Fri Apr 2022.Upside target0.33Upside target0.31Downside target0.3Downside target0.291 more row
Will Zomedica stock go up in 2022?
Target values for the price of one Zomedica share for Nov 2022. The weighted average target price per Zomedica share in Nov 2022 is: 0.29. In Nov, the positive dynamics for Momo shares will prevail with possible monthly volatility of 17.333% volatility is expected.Apr 11, 2022
What is Zomedica target price?
Stock Price TargetsHigh$1.20Median$1.20Low$1.20Average$1.20Current Price$0.35
Initial sales of a key product may be lower than investors were hoping for
Joe honed his investing skills as an analyst for Stock Advisor. He battle-tested his investment philosophy and strategies as portfolio manager of Tier 1, a market-crushing Motley Fool real-money portfolio that delivered 24.58% annualized returns.
What happened
Shares of Zomedica Pharmaceuticals ( NYSEMKT:ZOM) fell 13.7% on Thursday after the veterinary health company announced a change to its sales strategy.
So what
Zomedica will build out its internal sales team as it transitions away from its current distributor-based approach.
Now what
Zomedica recorded its first veterinarian sale of Truforma in mid-March. The diagnostic platform lies at the core of the company's commercial strategy and is likely to remain its only revenue generator for some time. Investors, in turn, are understandably concerned about a potential slower sales rollout for Truforma.
The veterinary health specialist is selling more shares than investors expected
Joe honed his investing skills as an analyst for Stock Advisor. He battle-tested his investment philosophy and strategies as portfolio manager of Tier 1, a market-crushing Motley Fool real-money portfolio that delivered 24.58% annualized returns.
What happened
Shares of Zomedica ( NYSEMKT:ZOM) fell 14% on Tuesday after the pet health company disclosed that it was increasing the size of its stock offering by nearly sevenfold.
So what
On Nov. 13, Zomedica announced commercialization plans for its Truforma diagnostic platform for cats and dogs. Its stock subsequently went on to soar a stunning 2,750%.
Now what
It's rare for a company to increase its share offering so significantly, especially at such a late hour. It's thus somewhat surprising that Zomedica's stock price didn't decline even more on Tuesday.
How much is the companion animal diagnostics market?
The market for companion animal diagnostics was $1.7 billion in 2019, which ZOM expects to rise to $2.8 billion by 2024 citing data from MarketsandMarkets. Even after the fall, ZOM stock has a market capitalization of $1.3 billion. This is more than double the forecasted 2025 market opportunity for companion animal diagnostics.
Is Zomedica a good company?
Zomedica is a niche company and is a good way to play the animal diagnostic market. According to Zomedica, nearly two-thirds of U.S. households have at least one pet and most of the households with a pet dog visit a veterinarian annually.
ZOM stock analysis
Shares briefly touched $2.98 at close on June 22 2018. By the end of the year, the price had fallen to $1.25, and to a low of $0.07 by September 9 2020.
Innovating for tomorrow
Zomedica remains in the development stage. It posts minimal revenue and a stream of losses. In 2019, the company recorded a £19.784m loss, which has improved slightly in 2020 to a loss of £16.9m.
Boom in pet ownership
Consumers built an “emotional stockpile” of pets to offer comfort and entertainment in the early months of the pandemic, according to the American Pet Products Association (APPA).
Key risks for Zomedica
Zomedica’s fundamentals can’t be ignored, even though they reflect the company’s forward-looking plans. The company posted a loss of $8.7m on $29,817 of revenue in the first half of 2021, with losses split evenly between quarters.
Zomedica stock price prediction
The small number of analysts offering a ZOM stock prediction remain pessimistic about the stock’s outlook, despite reductions to R&D costs and the promise of future revenue streams.
How much will the pet diagnostics market be in 2024?
consumers were expected to have spent $99 billion on their pets in 2020. The companion animal diagnostics market is forecast to reach $2.8 billion by 2024, at a compounded annual growth rate (CAGR) of 9.8% from 2019 to 2024.
What is the global companion animal diagnostics market?
The companion animal diagnostics market is forecast to reach $2.8 billion by 2024, at a compounded annual growth rate (CAGR) of 9.8% from 2019 to 2024. In addition, the global veterinary immunodiagnostic market has been predicted to expand at a CAGR of 9.6% and reach $2.1 billion by the year 2022.
Is Zomedica in the development stage?
Zomedica, which is in the development stage, recorded no revenues in 2020. The 2020 net loss resulted from research and development (“R&D”) expenses of approximately $8.0 million, general and administrative (“G&A”) expenses of approximately $6.0 million, and professional fees of approximately $2.2 million.
Why is Zomedica failing?
A significant reason why Zomedica may be failing to gain traction is that Truforma treats a small slice of the overall pet care market. If you’ve ever had to wait to receive lab results for your furry family members Ior yourself for that matter), then you understand the benefit of a point-of-care test.
Is Zomedica capitalized?
Also, although Zomedica is well capitalized at the moment, there is some concern that it may attempt to go on an acquisition spree. As Will Ashworth points out, the company’s new Vice President of Business Development has a history of completing acquisitions.
Does Zomedica have a moat?
However, the test is only applicable to specific conditions. And Zomedica does not have a moat in that space. One of the company’s strongest competitors is IDEXX Laboratories (NASDAQ: IDXX ). This doesn’t mean that there isn’t a market for Truforma.
Who is the CEO of Zomedica?
Zomedica's ascent began in January of this year, when it announced the arrival of a new CEO, Robert Cohen. Shortly thereafter, Reddit traders piled into the stock, causing it to grow explosively and putting it on the map for the first time.
When will Zomedica be available for dogs?
The biggest reason why people are talking about Zomedica right now is that Truforma is scheduled to launch on March 30. At launch, it'll be capable of five different diagnostic assays for cats and dogs. Two more assays will be out the door by the end of 2021.
